Daily valacyclovir reduces the risk of transmitting genital herpes (HSV-2) to a partner by about 48%. In the largest study on this question, published in the New England Journal of Medicine, the rate of a partner catching genital herpes dropped from 3.6% to 1.9% over eight months when the infected partner took valacyclovir every day. That’s a meaningful reduction, but not complete protection on its own.
How It Reduces Transmission
Most herpes transmission doesn’t happen during visible outbreaks. It happens during “subclinical shedding,” when the virus is active on the skin without causing any symptoms you can see or feel. This is what makes herpes so easy to pass along unknowingly.
Valacyclovir works by suppressing viral replication, which dramatically cuts down on these invisible shedding days. In clinical studies, people taking daily valacyclovir shed HSV-2 on about 2.4% of days, compared to 11% of days on placebo. That’s a 78% reduction in subclinical shedding. Fewer days of shedding means fewer opportunities for the virus to reach a partner.
Suppressive Therapy vs. Taking It Only During Outbreaks
There are two ways people use valacyclovir: daily (suppressive therapy) or only when an outbreak starts (episodic therapy). For preventing transmission, the daily approach is the one that matters. Episodic treatment shortens individual outbreaks but doesn’t address the subclinical shedding that happens between them. Since most transmission occurs without visible sores, taking it only during outbreaks does little to protect a partner.
The 48% transmission reduction seen in clinical trials specifically came from daily suppressive use. There is no comparable evidence that episodic use meaningfully lowers the chance of passing herpes to someone else.
Combining Valacyclovir With Condoms
The strongest protection comes from layering strategies. In the same large trial, condom use independently reduced transmission, and valacyclovir provided additional benefit on top of that. The most striking finding: among 141 couples where the infected partner took daily valacyclovir and the couple used condoms more than 90% of the time, zero partners acquired symptomatic genital herpes.
Neither method alone eliminates risk entirely. Valacyclovir cuts transmission by roughly half, and consistent condom use provides its own partial protection. Together, they bring the risk down substantially, though no combination can guarantee zero transmission since herpes can shed from skin areas a condom doesn’t cover.
What About Oral Herpes (HSV-1)?
The transmission data above applies specifically to genital HSV-2, which is where almost all the research has been done. For oral HSV-1 (cold sores), the picture is much less clear. Mathematical modeling studies suggest that current levels of antiviral treatment reduce HSV-1 transmission by somewhere between 0% and 2.5% at a population level. Even if a large percentage of cold sore recurrences were treated, models predict the overall prevalence of HSV-1 would decline by less than 5%.
This doesn’t necessarily mean valacyclovir is useless for an individual trying to avoid passing oral herpes to a partner. The drug does reduce HSV-1 shedding. But unlike genital HSV-2, there are no large clinical trials measuring whether daily valacyclovir actually prevents oral-to-oral or oral-to-genital HSV-1 transmission between specific couples. If you’re concerned about transmitting oral herpes, it’s worth discussing suppressive therapy with your provider, but the evidence base is far thinner than it is for genital herpes.
Protection During Pregnancy
Herpes transmission to a newborn during delivery is a separate but serious concern. Taking valacyclovir in late pregnancy reduces the chance of an active outbreak at the time of delivery, which lowers the risk of neonatal herpes. Studies have found that both acyclovir and valacyclovir used during pregnancy are not associated with an increase in birth defects, making them a reasonable option for pregnant people with a history of genital herpes. A Cochrane review confirmed the value of third-trimester antiviral prophylaxis for preventing recurrences at delivery.
How Long Before It Works
Valacyclovir begins suppressing viral replication within hours of the first dose, and shedding rates drop significantly within the first few days. However, the transmission studies enrolled participants who took the drug daily for months, so the protection data reflects consistent, ongoing use rather than a short course. There’s no well-defined “magic number” of days after which you’re fully protected. The key is daily consistency. Missing doses allows viral shedding to rebound, which undermines the protective effect.
Putting the Numbers in Context
A 48% reduction sounds modest as a percentage, but the absolute numbers tell a more practical story. In the landmark trial, the chance of a susceptible partner catching herpes over eight months was already relatively low at 3.6% with placebo. Daily valacyclovir cut that to 1.9%. Add consistent condom use, and the real-world risk per year for a cautious couple becomes quite small.
That said, herpes transmission is never zero in a serodiscordant relationship (where one partner has it and the other doesn’t). Valacyclovir is the single most effective pharmacological tool available for reducing that risk, but it works best as part of a broader strategy: daily medication, regular condom use, and avoiding sex during outbreaks or prodromal symptoms like tingling or itching. Together, these measures give couples a realistic way to maintain an intimate relationship while keeping transmission risk low.